The signaling mechanisms responsible for BCR/ABLinduced regulation of Mcl-1 expression in chronic myelogenous leukemia (CML) cells remain unclear. In this study, we show that BCR/ABL could upregulate sphingosine kinase-1 (SPK1) expression via multiple signal pathways, including mitogen-activated protein kinase (MAPK), phosphoinositide 3-kinase (PI3K) and Janus kinase 2 (JAK2), leading to increase cellular SPK1 activity in CML cells. 
Chronic myelogenous leukemia (CML) is a clonal myeloproliferative disease of hematopoietic progenitor cells transformed by bcr-abl oncogene, which is generated by the reciprocal translocation t (9; 22) (Sawyers, 1999) . The bcr-abl oncogene encodes P210 fusion protein that exhibits constitutive tyrosine kinase activity, leading to activation of multiple signaling molecules and upregulation of several targeted proteins (Lugo et al., 1990) . Myeloid cell leukemia-1 (Mcl-1), an antiapoptotic member of the bcl-2 family, has recently been identified as a BCR/ABL-dependent survival factor in CML (Aichberger et al., 2005) . However, the signaling mechanisms responsible for BCR/ABL-induced regulation of Mcl-1 expression in CML cells remain unclear. Recently, sphingosine kinase-1 (SPK1), the enzyme that phosphorylates sphingosine to form sphingosine-1-phosphate (S1P), could be activated by a number of growth factors and intracellular oncoproteins, and has been proven to be involved in signal transduction (Duan et al., 2004; Granata et al., 2004; Wattenberg et al., 2006) . SPK1 activation is involved in the multistep progression and multidrug resistance of leukemia (Le Scolan et al., 2005; Bonhoure et al., 2006) . Here, we show that SPK1 signal is also involved in the pathological progression of CML.
To elucidate the possible role of SPK1 signal in the pathology of CML, in our study the bcr-abl gene was transferred into murine fibroblast cell line NIH-3T3, murine interleukin-3-dependent pro-B-cell line Ba/F3 and human leukemia cell line HL-60. The SPK1 expression and cellular SPK activity of bcr-abl-transformed cells was compared with that of control cells. We found that overexpression of bcr-abl gene in fibroblast cells or leukemia cells results in upregulation of SPK1 expression ( Figure 1A ) and increase of cellular SPK activity ( Figure 1B ). To confirm that BCR/ABL could upregulate SPK1 expression and increase its cellular activity in CML cells, K562 cells were treated with different concentrations of STI 571, an abl tyrosine kinase inhibitor (Druker et al., 1996) , for different periods, SPK1 expression and the cellular SPK activity were detected. As shown in Figure 1C , STI571 treatment could decrease the SPK1 expression level and cellular SPK activity of K562 cells. Treatment of primary leukemia cells from CML patients with 2.5 mM STI571 for 6 h also results in decrease of cellular SPK1 activity ( Figure 1D ). These data indicated that BCR/ABL could upregulate SPK1 expression and increase its cellular activity in CML cells. It is known that BCR/ABL activates several signals, including mitogen-activated protein kinase, Janus kinase 2 (JAK2) and phosphoinositide 3-kinase (PI3K) in CML cells (Cortez et al., 1996; Skorski et al., 1997; Sillaber et al., 2000; Steelman et al., 2004; Samanta et al., 2006) . To examine the roles of these signals in SPK1 expression induced by BCR/ABL in CML cells, the bcr-abl-transformed BaF3 cells, BaF3/pLXSN and K562 cells were pretreated with PD98059, Wortmannin and AG490, specific inhibitors of extracellular signal-regulated kinase 1/2, PI3K and JAK2, respectively, and then the BCR/ABL-induced SPK1 activity and expression were assayed. As shown in Figure 2 , Wortmannin, PD98059 and AG490 could partly abolish the BCR/ABL-induced expression and cellular activity increase of SPK1, indicating that multiple signals are involving in BCR/ABL-induced SPK1 upregulation in CML cells. Among them, JAK2 signal has been proved to plays a critical role in the signal transduction of Bcr-Abl/Jak2/Gab2/PI3K/Akt/ GSK-3b network and mediates BCR/ABL-induced upregulation of c-Myc protein (Xie et al., 2002; Samanta et al., 2006) . As AG490 abolishes the BCR/ABLinduced SPK1 expression mostly, JAK2 seems to be also the major signal in this process.
Mcl-1 ensures the homeostasis of early hematopoietic progenitors and acts as an antiapoptotic factor in various neoplastic cells, including several leukemiaderived cell lines (Zhou et al., 1997; Opferman et al., 2005) . Mcl-1 also contributes to the pathogenesis of CML. Primary CML cells and CML cell lines express Mcl-1 in a constitutive manner. BCR/ABL promotes the Figure 2 Multiple signals mediate BCR-ABL-induced upregulation of SPK1. BaF3/pLXSN, BaF3/BCR-ABL and K562 cells were pretreated with PD98059 (50 mM), wortmannin (10 mM) and AG490 (25 mM) for 12 h. Then the cells were lysed and the SPK1 activity and expression were assayed. Analysis of [g-32 P] S1P was performed by thin-layer chromatography (a). Intensities of signals were determined by densitometry and shown relative to control arbitrarily normalized to 1. Data are mean7s.e. of triplicates assays (b). Expression of SPK1 was detected by immunoblotting with antibody to SPK1 (c). SPK1, sphingosine kinase-1. expression of Mcl-1 through the activation of RAS/ RAF/MAP kinase pathway (Aichberger et al., 2005) . Recently, several reports have shown that SPK1 and S1P signaling is associated with regulating the expression of bcl-2 family genes (Bektas et al., 2005; Limaye et al., 2005) . Given the fact that both SPK1-and Mcl-1-mediated suppressive effect of BCR/ABL could induce the survival and proliferation of CML cells, we further checked whether SPK1 is involved in BCR/ABLinduced upregulation of Mcl-1 expression. As shown in Figure 3A , the overexpression of bcr-abl gene induces upregulation of Mcl-1 in Ba/F3 cells. And retrovirusmediated overexpression of SPK1 gene results in increase of cellular SPK1 activity, also in upregulation (Yatomi et al., 1996; Wu et al., 2004) and STI571, the pharmacologic inhibitors of SPK1 and BCR/ABL, on the expression of Mcl-1 in bcr-abl À and bcr-abl þ cells were observed, respectively. Treatment of K562 and bcr-abl-transformed Ba/F3 cells with STI571 resulted in a slightly decrease in expression of Mcl-1. DMS treatment decreases the expression and activity of SPK1 ( Figure 3D ) and also downregulates the expression of Mcl-1 in BaF3/BCR-ABL cells ( Figure 3E) , and enhances the inhibitory effect of STI571 ( Figure 3F ). It is indicated that SPK1 is involved in the BCR/ABLinduced upregulation of Mcl-1 in CML cells.
In conclusion, we have demonstrated that BCR/ABL upregulates expression and cellular activity of SPK1 in CML cells. SPK1 signal also contributes to BCR-ABLinduced upregulation of Mcl-1 expression. SPK1 silencing significantly enhances apoptosis of CML cells induced by STI571. These data suggest that SPK1 might become a novel therapeutic target for CML. (Ad-SPK1) . The 64nt oligonucleotide encoding human SPK1 siRNA was inserted into BglII and HindIII sites of pShuttle-H1 to get pShuttle-H1-SPK1. The resultant plasmid was linearized with PmeI and co-transformed into Escherichia coli BJ5183 cells with pAdEasy-1/F11P adenoviral backbone plasmid (Lu et al, 2006) . Recombinants (AdH1-SPK1) were selected for kanamycin resistance and confirmed by PacI analysis. AdH1-SPK1 was linearized with PacI and transfected into AD-293 packaging cells to produce recombinant adenovirus (a). In AdH1-SPK1, but not Ad-H1 (empty)-infected K562 cells, SPK1 gene was efficiently silenced both 48 and 72 h after infection. Protein was extracted from cells, and SPK1 levels were checked by western blotting. SPK activity was also assayed. The actin bands served as internal control for equal total protein loading and specificity control. AdH1-SPK1, but not AdH1 (empty), significantly downregulated the expression of SPK1 gene ( 
